{"cell_type":{"a1e620e8":"code","9fa9c68b":"code","24527b5d":"code","1d206cd3":"code","134a3d5d":"code","9ab4c589":"code","d0401bad":"code","909a43ce":"code","c33a9bd6":"code","2e2db3d6":"code","ac7ebdb8":"code","8861f812":"code","24fc76d3":"code","10905a8b":"code","73c90212":"code","0fe744c8":"code","4e5f69e5":"code","fa9472bb":"code","685dc9b9":"code","14ac6bbd":"code","3015cc7e":"code","88b6c7e4":"code","45cb4c0c":"code","d32e0221":"code","449bd526":"code","8298e84a":"markdown","b5a5fb27":"markdown","b0da1006":"markdown","e016cde3":"markdown","5d92f2ab":"markdown","b0f18e87":"markdown","5a146268":"markdown","973db899":"markdown","a97af1e7":"markdown","df0674ad":"markdown","2ba3ef30":"markdown","29318cb2":"markdown","a16d48f9":"markdown","6fa7850a":"markdown","391ab2ec":"markdown","fbcbc341":"markdown","eba8bbf9":"markdown","3fe78c6d":"markdown","932816b6":"markdown","6d0e01e0":"markdown","d5314967":"markdown"},"source":{"a1e620e8":"! pip install gensim==3.4.0","9fa9c68b":"import os\nimport pandas as pd\nfrom gensim.models.fasttext import FastText as FT_gensim\nimport nltk\nnltk.download('punkt')\nfrom nltk.tokenize import sent_tokenize\nfrom uuid import uuid4\nimport torch\nimport re\nimport json\nfrom tqdm import tqdm\nimport datetime\nimport pprint\nimport random\nimport string\nimport sys","24527b5d":"# main folder of Covid19 Dataset\ndirs = [\"biorxiv_medrxiv\", \"comm_use_subset\", \"custom_license\", \"noncomm_use_subset\"]\ndocs = []\nbase_path = \"\/kaggle\/input\/CORD-19-research-challenge\"\nfor d in dirs:\n    for file in tqdm(os.listdir(f\"{base_path}\/{d}\/{d}\/pdf_json\")):\n        file_path = f\"{base_path}\/{d}\/{d}\/pdf_json\/{file}\"\n        json_file = json.load(open(file_path,\"rb\"))\n        \n        title = json_file[\"metadata\"][\"title\"]\n        try : \n            abstract = \"\\n\\n\".join([text[\"text\"] for text in json_file[\"abstract\"]])\n        except : \n            abstract = \"\"\n        full_text = \"\\n\\n\".join([text[\"text\"] for text in json_file[\"body_text\"]])\n        docs.append([title, abstract, full_text])\n# Pandas Dataframe containing the title, abstract and body text\npapers_df = pd.DataFrame(docs, columns = [\"title\", \"abstract\", \"full_text\"])","1d206cd3":"papers_df = papers_df.dropna()\npapers_df","134a3d5d":"# Upload the model \nmodel_load_name = 'final_model_gensim.pt'\npath = F\"\/kaggle\/input\/similaritymodels2new\/Similarity\/FinalModel\/{model_load_name}\"\nmodel = FT_gensim.load(path)","9ab4c589":"def token_similarity(token1, token2): \n    \"\"\"\n    calculate similarity between sentences based on their embeddings\n        ----------------\n    Args : \n        token1 : String\n        token1 : String\n        ---------------\n    returns:\n        float between 0 and 100, representing the percentage of similarity\n    \"\"\"\n    try :\n        token1 = re.sub('[^a-zA-z0-9\\s]', '' , token1).lower()\n        token2 = re.sub('[^a-zA-z0-9\\s]', '' , token2).lower()\n        return model.similarity(token1, token2)\n    except : \n        return 0\n\ndef get_context(query, search_on, model = model, df = papers_df):\n    \"\"\"\n    maps similarity function for given query to either all paper abstracts or to all paper titles to extract the closes paper to answer the query.\n        ----------------\n    Args : \n        query : String\n        search_on : String\n        model : Gensim model Object\n        df : pandas Dataframe\n        ---------------\n    returns:\n        Tuple containing full_text, title and similarity degree to closeset paper to query.\n    \"\"\"\n    \n    if search_on in [\"title\", \"abstract\"]:\n        df[\"similarity_to_query\"] = df[search_on].apply(lambda x : token_similarity(x, query))\n        result = df.nlargest(1, ['similarity_to_query']).reset_index(drop = True)\n        return result[\"full_text\"][0].replace(\"\\n\", \" \"), result[\"title\"][0], result[\"similarity_to_query\"][0]\n    else :\n        raise Exception(\"search_on argument should be in ['title', 'abstract']\")","d0401bad":"query = \"what are risk factors COVID-19?\"\nsearch_on = \"title\"\nimport time\nt1 = time.time()\ncontext = get_context(query, search_on, model, papers_df)\nt2 = time.time()\nprint(f\"query took {t2-t1} seconds\")\nprint(context)","909a43ce":"\nquestion_list = \"\"\" What is known about transmission, incubation, and environmental stability\nWhat do we know about natural history, transmission, and diagnostics for the virus \nWhat have we learned about infection prevention and control\nWhat is Range of incubation periods for the disease in humans (and how this varies across age and health status) and how long individuals are contagious, even after recovery.\nWhat is Prevalence of asymptomatic shedding and transmission (e.g., particularly children).\nWhat is Seasonality of transmission.\nWhat is Physical science of the coronavirus (e.g., charge distribution, adhesion to hydrophilic\/phobic surfaces, environmental survival to inform decontamination efforts for affected areas and provide information about viral shedding).\nWhat is Persistence and stability on a multitude of substrates and sources (e.g., nasal discharge, sputum, urine, fecal matter, blood).\nWhat is Persistence of virus on surfaces of different materials (e,g., copper, stainless steel, plastic).\nWhat is Natural history of the virus and shedding of it from an infected person\nWhat is Implementation of diagnostics and products to improve clinical processes\nWhat is Disease models, including animal models for infection, disease and transmission\nWhat is Tools and studies to monitor phenotypic change and potential adaptation of the virus\nWhat is Immune response and immunity\nWhat is Effectiveness of movement control strategies to prevent secondary transmission in health care and community settings\nWhat is Effectiveness of personal protective equipment (PPE) and its usefulness to reduce risk of transmission in health care and community settings\nWhat is Role of the environment in transmission\nWhat are the potential risks factors of Covid-19\nWhat is the influence of Smoking, pre-existing pulmonary disease on Covid-19\nWill Co-infections and other co-morbidities co-existing respiratory\/viral infections make the virus more transmissible or virulent \nRisk factors associated with Neonates and pregnant women\nWhat are the risk factors associated with Socio-economic and behavioral factors to understand the economic impact of Covid19.\nWhat are the Transmission dynamics of the virus, including the basic reproductive number, incubation period, serial interval, modes of transmission and environmental factors\nWhat is the Severity of disease, including risk of fatality among symptomatic hospitalized patients, and high-risk patient groups\nWhat is Susceptibility of populations for covid19 rik factors\nWhat are Public health mitigation measures that could be effective for control of covid19\nWhat do we know about virus genetics, origin, and evolution\nWhat do we know about the virus origin and management measures at the human-animal interface\nReal-time tracking of whole genomes and a mechanism for coordinating the rapid dissemination of that information to inform the development of diagnostics and therapeutics and to track variations of the virus over time.\nAccess to geographic and temporal diverse sample sets to understand geographic distribution and genomic differences, and determine whether there is more than one strain in circulation. Multi-lateral agreements such as the Nagoya Protocol could be leveraged.\nEvidence that livestock could be infected (e.g., field surveillance, genetic sequencing, receptor binding) and serve as a reservoir after the epidemic appears to be over.\nEvidence of whether farmers are infected, and whether farmers could have played a role in the origin.\nSurveillance of mixed wildlife- livestock farms for SARS-CoV-2 and other coronaviruses in Southeast Asia.\nExperimental infections to test host range for this pathogen.\nAnimal host(s) and any evidence of continued spill-over to humans\nSocioeconomic and behavioral risk factors for this spill-over\nSustainable risk reduction strategies\nWhat do we know about vaccines and therapeutics\nWhat has been published concerning research and development and evaluation efforts of vaccines and therapeutics\nWhat is Effectiveness of drugs being developed and tried to treat COVID-19 patients.\nWhat is Clinical and bench trials to investigate less common viral inhibitors against COVID-19 such as naproxen, clarithromycin, and minocyclinethat that may exert effects on viral replication.\nMethods evaluating potential complication of Antibody-Dependent Enhancement (ADE) in vaccine recipients.\nExploration of use of best animal models and their predictive value for a human vaccine.\nCapabilities to discover a therapeutic (not vaccine) for the disease, and clinical effectiveness studies to discover therapeutics, to include antiviral agents.\nAlternative models to aid decision makers in determining how to prioritize and distribute scarce, newly proven therapeutics as production ramps up. This could include identifying approaches for expanding production capacity to ensure equitable and timely distribution to populations in need.\nEfforts targeted at a universal coronavirus vaccine.\nEfforts to develop animal models and standardize challenge studies\nEfforts to develop prophylaxis clinical studies and prioritize in healthcare workers\nApproaches to evaluate risk for enhanced disease after vaccination\nAssays to evaluate vaccine immune response and process development for vaccines, alongside suitable animal models [in conjunction with therapeutics\nWhat has been published about medical care\nWhat has been published concerning surge capacity and nursing homes\nWhat has been published concerning efforts to inform allocation of scarce resources\nWhat do we know about personal protective equipment\nWhat has been published concerning alternative methods to advise on disease management\nWhat has been published concerning processes of care? What do we know about the clinical characterization and management of the virus\nResources to support skilled nursing facilities and long term care facilities.\nMobilization of surge medical staff to address shortages in overwhelmed communities\nAge-adjusted mortality data for Acute Respiratory Distress Syndrome (ARDS) with\/without other organ failure \u2013 particularly for viral etiologies\nExtracorporeal membrane oxygenation (ECMO) outcomes data of COVID-19 patients\nOutcomes data for COVID-19 after mechanical ventilation adjusted for age.\nKnowledge of the frequency, manifestations, and course of extrapulmonary manifestations of COVID-19, possible cardiomyopathy and cardiac arrest.\nApplication of regulatory standards (EUA, CLIA) and ability to adapt care to crisis standards of care level.\nApproaches for encouraging and facilitating the production of elastomeric respirators, which can save thousands of N95 masks.\nBest telemedicine practices, barriers and faciitators, and specific actions to remove\/expand them within and across state boundaries.\nGuidance on the simple things people can do at home to take care of sick people and manage disease.\nOral medications that might potentially work.\nUse of AI in real-time health care delivery to evaluate interventions, risk factors, and outcomes in a way that could not be done manually.\nBest practices and critical challenges and innovative solutions and technologies in hospital flow and organization, workforce protection, workforce allocation, community-based support resources, payment, and supply chain management to enhance capacity, efficiency, and outcomes.\nEfforts to define the natural history of disease to inform clinical care, public health interventions, infection prevention control, transmission, and clinical trials\nEfforts to develop a core clinical outcome set to maximize usability of data across a range of trials\nEfforts to determine adjunctive and supportive interventions that can improve the clinical outcomes of infected patients (e.g. steroids, high flow oxygen)\nWhat do we know about the effectiveness of non-pharmaceutical interventions\nWhat is known about equity and barriers to compliance for non-pharmaceutical interventions\nHow can we use Guidance on ways to scale up NPIs in a more coordinated way (e.g., establish funding, infrastructure and authorities to support real time, authoritative (qualified participants) collaboration with all states to gain consensus on consistent guidance and to mobilize resources to geographic areas where critical shortfalls are identified) to give us time to enhance our health care delivery system capacity to respond to an increase in cases.\nRapid design and execution of experiments to examine and compare NPIs currently being implemented. DHS Centers for Excellence could potentially be leveraged to conduct these experiments.\nRapid assessment of the likely efficacy of school closures, travel bans, bans on mass gatherings of various sizes, and other social distancing approaches.\nMethods to control the spread in communities, barriers to compliance and how these vary among different populations..\nModels of potential interventions to predict costs and benefits that take account of such factors as race, income, disability, age, geographic location, immigration status, housing status, employment status, and health insurance status.\nPolicy changes necessary to enable the compliance of individuals with limited resources and the underserved with NPIs.\nResearch on why people fail to comply with public health advice, even if they want to do so (e.g., social or financial costs may be too high).\nResearch on the economic impact of this or any pandemic. This would include identifying policy and programmatic alternatives that lessen\/mitigate risks to critical government services, food distribution and supplies, access to critical household supplies, and access to health diagnoses, treatment, and needed care, regardless of ability to pay.\nWhat do we know about diagnostics and surveillance\nWhat has been published concerning systematic, holistic approach to diagnostics (from the public health surveillance perspective to being able to predict clinical outcomes)\nHow widespread current exposure is to be able to make immediate policy recommendations on mitigation measures. Denominators for testing and a mechanism for rapidly sharing that information, including demographics, to the extent possible. Sampling methods to determine asymptomatic disease (e.g., use of serosurveys (such as convalescent samples) and early detection of disease (e.g., use of screening of neutralizing antibodies such as ELISAs).\nEfforts to increase capacity on existing diagnostic platforms and tap into existing surveillance platforms.\nRecruitment, support, and coordination of local expertise and capacity (public, private\u2014commercial, and non-profit, including academic), including legal, ethical, communications, and operational issues.\nNational guidance and guidelines about best practices to states (e.g., how states might leverage universities and private laboratories for testing purposes, communications to public health officials and the public).\nDevelopment of a point-of-care test (like a rapid influenza test) and rapid bed-side tests, recognizing the tradeoffs between speed, accessibility, and accuracy.\nRapid design and execution of targeted surveillance experiments calling for all potential testers using PCR in a defined area to start testing and report to a specific entity. These experiments could aid in collecting longitudinal samples, which are critical to understanding the impact of ad hoc local interventions (which also need to be recorded).\nSeparation of assay development issues from instruments, and the role of the private sector to help quickly migrate assays onto those devices.\nEfforts to track the evolution of the virus (i.e., genetic drift or mutations) and avoid locking into specific reagents and surveillance\/detection schemes.\nLatency issues and when there is sufficient viral load to detect the pathogen, and understanding of what is needed in terms of biological and environmental sampling.\nUse of diagnostics such as host response markers (e.g., cytokines) to detect early disease or predict severe disease progression, which would be important to understanding best clinical practice and efficacy of therapeutic interventions.\nPolicies and protocols for screening and testing.\nPolicies to mitigate the effects on supplies associated with mass testing, including swabs and reagents.\nTechnology roadmap for diagnostics.\nBarriers to developing and scaling up new diagnostic tests (e.g., market forces), how future coalition and accelerator models (e.g., Coalition for Epidemic Preparedness Innovations) could provide critical funding for diagnostics, and opportunities for a streamlined regulatory environment.\nNew platforms and technology (e.g., CRISPR) to improve response times and employ more holistic approaches to COVID-19 and future diseases.\nCoupling genomics and diagnostic testing on a large scale.\nEnhance capabilities for rapid sequencing and bioinformatics to target regions of the genome that will allow specificity for a particular variant.\nEnhance capacity (people, technology, data) for sequencing with advanced analytics for unknown pathogens, and explore capabilities for distinguishing naturally-occurring pathogens from intentional.\nOne Health surveillance of humans and potential sources of future spillover or ongoing exposure for this organism and future pathogens, including both evolutionary hosts (e.g., bats) and transmission hosts (e.g., heavily trafficked and farmed wildlife and domestic food and companion species), inclusive of environmental, demographic, and occupational risk factors.\nWhat has been published concerning ethical considerations for research\nWhat has been published concerning social sciences at the outbreak response\nEfforts to articulate and translate existing ethical principles and standards to salient issues in COVID-2019\nEfforts to embed ethics across all thematic areas, engage with novel ethical issues that arise and coordinate to minimize duplication of oversight\nEfforts to support sustained education, access, and capacity building in the area of ethics\nEfforts to establish a team at WHO that will be integrated within multidisciplinary research and operational platforms and that will connect with existing and expanded global networks of social sciences.\nEfforts to develop qualitative assessment frameworks to systematically collect information related to local barriers and enablers for the uptake and adherence to public health measures for prevention and control. This includes the rapid identification of the secondary impacts of these measures. (e.g. use of surgical masks, modification of health seeking behaviors for SRH, school closures)\nEfforts to identify how the burden of responding to the outbreak and implementing public health measures affects the physical and psychological health of those providing care for Covid-19 patients and identify the immediate needs that must be addressed.\nEfforts to identify the underlying drivers of fear, anxiety and stigma that fuel misinformation and rumor, particularly through social media.\nWhat has been published about information sharing and inter-sectoral collaboration\nWhat has been published about data standards and nomenclature\nWhat has been published about governmental public health\nWhat do we know about risk communication\nWhat has been published about communicating with high-risk populations\nWhat has been published to clarify community measures\nWhat has been published about equity considerations and problems of inequity\nMethods for coordinating data-gathering with standardized nomenclature.\nSharing response information among planners, providers, and others.\nUnderstanding and mitigating barriers to information-sharing.\nHow to recruit, support, and coordinate local (non-Federal) expertise and capacity relevant to public health emergency response (public, private, commercial and non-profit, including academic).\nIntegration of federal\/state\/local public health surveillance systems.\nValue of investments in baseline public health response infrastructure preparedness\nModes of communicating with target high-risk populations (elderly, health care workers).\nRisk communication and guidelines that are easy to understand and follow (include targeting at risk populations\u2019 families too).\nCommunication that indicates potential risk of disease to all population groups.\nMisunderstanding around containment and mitigation.\nAction plan to mitigate gaps and problems of inequity in the Nation\u2019s public health capability, capacity, and funding to ensure all citizens in need are supported and can access information, surveillance, and treatment.\nMeasures to reach marginalized and disadvantaged populations.\nData systems and research priorities and agendas incorporate attention to the needs and circumstances of disadvantaged populations and underrepresented minorities.\nMitigating threats to incarcerated people from COVID-19, assuring access to information, prevention, diagnosis, and treatment.\nUnderstanding coverage policies (barriers and opportunities) related to testing, treatment, and care\n\"\"\"\n\nquestion_list = question_list.split(\"\\n\")\nqa_dataframe = pd.DataFrame({\"Questions\": question_list})","c33a9bd6":"qa_dataframe[\"Context\"] = qa_dataframe[\"Questions\"].apply(lambda x : get_context(x, \"title\", model, papers_df)[0])","2e2db3d6":"qa_dataframe","ac7ebdb8":"!pip install tensorflow==1.15.2","8861f812":"import tensorflow as tf\nprint(tf.version)","24fc76d3":"covidQuestions = qa_dataframe","10905a8b":"! mkdir temp","73c90212":"covidQuestions.to_json('temp\/QnAInput.json')","0fe744c8":"#Test File\n\nimport json\nfrom uuid import uuid4\n\ndef restructure_json_Test(input_data):  \n    \n    \"\"\"\n    Restructure input data to be compatible with BIOBERT Qna test data format.\n        ----------------\n    Args : \n        input_data : String\n        ---------------\n    returns:\n        formatted data in dictionary\n    \"\"\"\n    output = dict()\n    data = []\n    paragraphs = []\n    for i in input_data[\"Questions\"].keys():\n        qas = []\n        answers = []\n      \n        qas.append({\"id\" : str(uuid4()),\n                   \"question\" : input_data[\"Questions\"][i],\n                   })\n        paragraphs = paragraphs + [{\"qas\" : qas, \"context\" : input_data[\"Context\"][i]}]\n    data = data + [{\"paragraphs\" : paragraphs, \"title\" : \"BioASQ6b\"}]\n    output[\"data\"] = data\n    output[\"version\"] = \"BioASQ6b\"\n    return output","4e5f69e5":"with open('temp\/QnAInput.json',encoding='ISO-8859-1' ) as f:\n    input_data = json.load(f)","fa9472bb":"outputData = restructure_json_Test(input_data)\nwith open('temp\/QnAInputTest.json', 'w',  encoding='ISO-8859-1') as json_file:\n    json.dump(outputData, json_file)","685dc9b9":"! ls -l '\/kaggle\/input\/biobertcode\/GitRepo\/BIOBERT\/bioasq-biobert\/run_factoid.py'\n! ls -l '\/kaggle\/input\/biobertconfig\/biobertconfig\/vocab.txt'\n! ls -l '\/kaggle\/input\/biobertconfig\/biobertconfig\/bert_config.json'\n! ls -l '\/kaggle\/input\/biobertmodel2\/BERT-pubmed-1000000-SQuAD2\/model.ckpt-14470.index'\n! ls -l 'temp\/QnAInputTest.json'","14ac6bbd":"! python \/kaggle\/input\/biobertcode\/GitRepo\/BIOBERT\/bioasq-biobert\/run_factoid.py \\\n     --do_train=False \\\n     --do_predict=True \\\n     --vocab_file=\/kaggle\/input\/biobertconfig\/biobertconfig\/vocab.txt \\\n     --bert_config_file=\/kaggle\/input\/biobertconfig\/biobertconfig\/bert_config.json \\\n     --init_checkpoint=\/kaggle\/input\/biobertmodel2\/BERT-pubmed-1000000-SQuAD2\/model.ckpt-14470.index \\\n     --max_seq_length=512 \\\n     --max_answer_length=256 \\\n     --train_batch_size=12 \\\n     --learning_rate=5e-6 \\\n     --doc_stride=128 \\\n     --num_train_epochs=1.0 \\\n     --do_lower_case=False \\\n     --train_file=$BIOASQ_INPUT_DIR\/BioASQ-6b\/train\/Full-Abstract\/BioASQ-train-factoid-6b-full-annotated.json \\\n     --predict_file=temp\/QnAInputTest.json \\\n     --output_dir=\/kaggle\/output\/kaggle\/factoid_output\/prediction\/","3015cc7e":"ls -l \/kaggle\/output\/kaggle\/factoid_output\/prediction\/predictions.json","88b6c7e4":"with open('\/kaggle\/output\/kaggle\/factoid_output\/prediction\/predictions.json',encoding='ISO-8859-1' ) as f:\n    output_data = json.load(f)","45cb4c0c":"output_data","d32e0221":"with open('temp\/QnAInputTest.json',encoding='ISO-8859-1' ) as f:\n    output_data_questions = json.load(f)","449bd526":"paragraphs = output_data_questions['data'][0]['paragraphs']\n\nfor index, item in enumerate(paragraphs):\n    id = item['qas'][0]['id']\n    question = item['qas'][0]['question']\n    answer = output_data[id]\n    print(\"Question \", str(index + 1), \" : \" , question ,\"\\n Answer : \", answer)\n    print(\"\\n\")","8298e84a":"COVID-19 Open Research Dataset (CORD-19) Analysis\n======\n\nCOVID-19 Open Research Dataset (CORD-19) is a free resource of scholarly articles, aggregated by a coalition of leading research groups, about COVID-19 and the coronavirus family of viruses. The dataset can be found on [Semantic Scholar](https:\/\/pages.semanticscholar.org\/coronavirus-research) and there is a research challenge on [Kaggle](https:\/\/www.kaggle.com\/allen-institute-for-ai\/CORD-19-research-challenge).\n\nBERT - Bidirectional Encoder Representations from Transformers, is a new method of pre-training language representations which obtains state-of-the-art results on a wide array of Natural Language Processing (NLP) tasks: https:\/\/github.com\/google-research\/bert, We use derivation of BERT model as BioBERT to come up with answers for set of questions listed in the challenge, First step is to use sentence embeddings by using FastText in gensim and come up with context for questions.\n\n\nSecond step is to use that context and feed set of questions and their respective context in BioBERT model","b5a5fb27":"# Test Data preparation","b0da1006":"### Installing Gensim library which will be used to load FastText embeddings for Sentence vectors to find context, \n\nNote: need to maintain version as 3.8.0 had compaitibility issues","e016cde3":"# Prediction using Fine Tuned BIOBERT model\n\nBioBERT model has been uploaded to https:\/\/www.kaggle.com\/varshnes\/biobertmodel2","5d92f2ab":" # BioBERT - BERT model trained on corpus: \n ## This repository provides the code for fine-tuning BioBERT, a biomedical language representation model designed for biomedical text mining tasks such as biomedical named entity recognition, relation extraction, and question answering, Github code: https:\/\/github.com\/dmis-lab\/biobert\n### We have used question answering side of BioBERT model to find answer in COVID-19 Challenge","b0f18e87":"Check the prediction file in output folder","5a146268":"### Lets go through Task 2 Questions 1 by 1 and predictions are mapped to output side by side answers","973db899":"Create temp directory to store temporary files","a97af1e7":"### Test the query","df0674ad":"### Eliminate empty papers","2ba3ef30":"### Since BERT model was trained using tf1.x, we can not use transfer learning of using pre-trained weights on tensorflow 2.0 so need to installing Tensorflow version 1.x","29318cb2":"### Upload Pretrained FastText Embeddings Model","a16d48f9":"### Function to campare similary between input query and each paper title or paper abstract","6fa7850a":"### Indexing all 45,000 research papers into pandas dataframe with Title, Abstract and Full text body","391ab2ec":"TPU support is not available for Tensorflow version 1.x in Kaggle.","fbcbc341":"Save the restructured data in JSON format","eba8bbf9":"Extracting context from the data ingestion module above using Fast Text model","3fe78c6d":"Format the dataframe to create a JSON as input to BIOBERT QnA model","932816b6":"### Task-1 Questions to be answered","6d0e01e0":"## BIOBERT Fine-tuning and Prediction","d5314967":"Verify all files used for prediction"}}